Affordable Access

Publisher Website

Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry

Authors
Journal
Journal of Chromatography B
1570-0232
Publisher
Elsevier
Publication Date
Volume
819
Issue
1
Identifiers
DOI: 10.1016/j.jchromb.2005.01.027
Keywords
  • Gefitinib
  • Zd1839
  • Lc/Ms/Ms
  • Pharmacokinetics
Disciplines
  • Biology

Abstract

Abstract A rapid, sensitive and specific method was developed and validated using liquid chromatography–tandem mass spectrometry (LC/MS/MS) for determination of gefitinib in human plasma and mouse plasma and tissue. Sample preparation involved a single protein precipitation step by the addition of 0.1 mL of plasma or a 200 mg/mL tissue homogenate diluted 1/10 in human plasma with 0.3 mL acetonitrile. Separation of the compounds of interest, including the internal standard (d8)-gefitinib, was achieved on a Waters X-Terra™ C 18 (50 mm × 2.1 mm i.d., 3.5 μm) analytical column using a mobile phase consisting of acetonitrile–water (70:30, v/v) containing 0.1% formic acid and isocratic flow at 0.15 mL/min for 3 min. The analytes were monitored by tandem mass spectrometry with electrospray positive ionization. Linear calibration curves were generated over the range of 1–1000 ng/mL for the human plasma samples and 5–1000 ng/mL for mouse plasma and tissue samples with values for the coefficient of determination of >0.99. The values for both within- and between-day precision and accuracy were well within the generally accepted criteria for analytical methods (<15%). This method was subsequently used to measure concentrations of gefitinib in mice following administration of a single dose of 150 mg/kg intraperitoneally and in cancer patients receiving an oral daily dose of 250 mg.

There are no comments yet on this publication. Be the first to share your thoughts.